Search Grants — Free, No Account Required

NIAID - National Institute of Allergy and Infectious Diseases

Project Summary/Abstract Public Health Problem. According to the World Health Organization (WHO), approximately 39 million people are currently living with HIV worldwide. Out of these, about 1.3 million were newly infected in 2022 alone. Moreover, around 630,000 people died from AIDS-related illnesses in the same year. Despite significant advances in therapies and accessibility to care and prevention methods HIV remains a global health challenge. The HIV epidemic has had a severe impact on vulnerable populations, exacerbating existing inequalities. Women and girls are disproportionately affected, accounting for over half of all new HIV infections globally. Despite antiretroviral (ART) initiation upon HIV diagnosis recommended by the 2019 U.S. guidelines, the current chronic-treated and untreated HIV-infected population is >375,000 people in the U.S. alone, and HIV continues to be routinely diagnosed during chronic infection. How Our Product Meets Unmet Needs. Jan Biotech has developed a nonezymatic, chemical amplification and direct detection assay for HIV RNA. The HIVLatentDetect assay provides quick, sensitive, and quantitative measurement of cell-based HIV RNAs in HIV-infected individuals who are fully suppressed under antiretroviral treatment, including for 100% of acute/early HIV-infection treated individuals, for which QVOA, qPCR, ddPCR, IPDA, and single viral copy assays show a ≥25% rate of assay failure or no detection. Jan Biotech’s HIVLD assay provided an unprecedented 0.97 (p-value≤0.0001) predictive value for time to HIV viral rebound after antiretroviral treatment interruption for the acute/early treated cohort in the AIDS Clinical Trials Group (ACTG) A5345. Jan Biotech’s assay would provide a much needed change to HIV standard of care, from viral load testing to detection of reservoir size predictive of, and prior to, plasma viral load changes. HIVLD provides a novel minimal residual disease (MRD) measurement to allow patients and clinicians to make earlier decisions for improving patient care. An MRD assay that captures the replication-competent fraction of chronic HIV reservoirs will allow safer participant involvement in clinical trials investigating new and potential cure or remission treatments. In the long term, HIV MRD testing will facilitate efforts to achieve a functional cure or fully eliminate HIV. Summary of Approach. The proposed work would allow Jan Biotech to expand the assay’s predictive value for time to HIV viral rebound after treatment interruption for the vast chronic-treated HIV-infected population, and to investigate the assay’s value for novel minimal residual disease (MRD) measurements to allow patients and clinicians to make earlier decisions for improving patient care and monitoring response of individual’s chronic HIV reservoir to potential cure treatments. Jan Biotech’s assay of all participating ACTG A5345 assays best captures the functional differences in the HIV reservoir leading to differences in viral rebound time between chronic- and acute/early-treated populations. Collaborators and Unique Resources. Jan Biotech, Inc., with expertise in molecular diagnostic development, will continue to collaborate with Dr. John W. Mellors, University of Pittsburgh School of Public Health; Dr. Michael Keefer, University of Rochester; Dr. Harris Gelbard, Director of the Center for Neurotherapeutics Discovery (CND) and Professor of Neurology, Pediatrics, Neuroscience and Microbiology & Immunology at the University of Rochester Medical Center; and the IVQAC team, led by Dr. Thomas Denny. Specific Aims Specific Aim 1 (Phase I): Develop HIVLD assay to differentiate chronic-treated HIV-1 subpopulations Specific Aim 2 (Phase II): Assay validation using ACTG clinical trial chronic-treated samples Specific Aim 3 (Phase II): Establish large scale clinical relevance for chronic HIV reservoir characterization Specific Aim 4 (Phase II): Software validation and verification for cHIVLD assay analytics Market after Completion. The goal of the proposed work is to develop this very promising technology to serve the vast chronic-HIV population by performing needed testing through HIV treatment interruption and large-scale population studies with well-characterized samples. The chronic-HIVLD assay (cHIVLD) is ideal for routine HIV testing, where it will provide minimal residual disease (MRD) measurements to allow patients and clinicians to make earlier decisions for improving patient care, and for HIV cure trial and research use to monitor the response of individuals’ chronic HIV reservoir to potential cure treatments.

NCI - National Cancer Institute

PROJECT SUMMARY This Academic-Industrial Partnership (AIP) grant aims to translate the MR cytometry imaging technique into a push-button imaging tool on clinical MRI platforms. MR cytometry imaging is an innovative, diffusion MRI based method that non-invasively measures mean cell size in vivo, thereby providing a powerful new way to characterize tissues for clinical applications. Investigators at Vanderbilt University Medical Center (Vanderbilt) and the University of Washington in Seattle (UW) will team up with Philips Healthcare (Philips), a major vendor and supplier of clinical MRI scanners, to optimize and implement innovative pulse sequences, and to integrate automated data analyses into Philips’ commercial platform that can be deployed widely to further assessments of the clinical role of MR cytometry imaging, particularly in breast cancer. The project builds on several years of previous NIH-funded research on diffusion MRI and a long-standing cooperation between Philips and Vanderbilt investigators. The proposal aims to fill the gap by bringing both the academic (Vanderbilt and UW) and industry (Philips) partners together to translate the MR cytometry imaging to state-of-the-art commercial platforms. This perfectly matches the goal of PAR-25-079 (Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems) to “identify and translate a novel technological solution towards detection /diagnosis or treatment of cancers”. We hereby identify the following specific aims: Aim 1 [prototype development] The Philips team will develop a prototype of the MR cytometry imaging tool for end users on their commercial MRI platform, including both data acquisition using oscillating gradient spin echo (OGSE) sequences and automated data analyses of MR cytometry imaging on Philips’s clinical platform. Aim 2 [protocol optimization]: The Vanderbilt team will further optimize MR cytometry imaging protocols for the most commonly-used gradient performances, particularly for breast cancer imaging, and develop a quality control (QC) protocol including a novel breast tumor cell size phantom to ensure the accuracy and stability of diffusion MRI and MR cytometry imaging measurements. Vertebrate animal models will be needed to generate three types of breast tumors with distinct mean cell sizes, which will then be dissociated into fixed cells to create the cell size phantom. This approach will allow the phantom to mimic the realistic cellular composition and size distribution of breast tumors, including cancer cells, immune cells, and stromal cells, making it well suited as a QC phantom for MR cytometry in breast imaging. Aim 3 [multi-site evaluation]: The product prototype of MR cytometry imaging will be comprehensively evaluated for accuracy, intra- and inter-session repeatability in breast cancer patients at multiple sites, including Vanderbilt Institute of Imaging Science, Vanderbilt Hospital, and UW Hospital. Upon completion, a reliable, easyto-use, and fully automated product prototype of MR cytometry imaging will be developed on Philips’s state-ofthe-art clinical MRI platform for end users in clinics. This provides a basis for more widespread applications of MR cytometry imaging in future cancer clinical trials.

NIAID - National Institute of Allergy and Infectious Diseases

PROJECT SUMMARY/ABSTRACT Cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. People with HIV (PWH) with virus suppression on antiretroviral therapy (ART) have a 2-fold increased risk of developing CVD compared to people without HIV (PWoH), even when controlling for age and traditional CVD risk factors. One factor that may contribute to the increased CVD in PWH is cytomegalovirus (CMV) coinfection. Nearly all PWH and about half of all adults without HIV in the United States have CMV, which is independently linked to CVD. In preliminary spatial transcriptomic analyses of vascular tissues of PWH and PWoH, all of whom have peripheral artery disease, we find that the proportion of myeloid cells in regions of interest (ROIs) across arteries is significantly higher in tissues from PWH. CMV can reactivate from latently-infected monocytes as they differentiate into macrophages, and virological and immunological evidence suggests that PWH have more frequent CMV reactivation events than do PWoH, so the cardiopathogenic effects of CMV may be more pronounced among PWH due to the increased numbers of macrophages harboring replicating CMV. We hypothesize that CMV reactivation in infiltrating macrophages provides antigenic signals for CMV-reactive T cells in vascular tissues. We will use the following Specific Aims to test this hypothesis. Aim 1: To define the spatial context of CMV expression in vascular tissues of PWH and PWoH. In Aim 1, we will test this hypothesis by (1) defining the spatial context of CMV expression in situ in vascular tissues of PWH and PWoH with and without CVD, (2) quantifying CMV expression in macrophages in vessels from PWH and PWoH with and without CVD, and (3) confirming spatial relationships of CD4 and CD8 T cells and CMV-expressing target cells in the vasculature. Aim 2. To determine if serum-derived MDMs from PWH with CMV are more effective at activating and presenting CMV antigens to T cells than are MDMs from PWoH with CMV. In Aim 2, we will use in vitro experiments to determine if serum-derived MDMs from PWH with CMV, which preserves the influence of systemic inflammatory mediators, are more effective at activating autologous T cells than MDMs from PWoH with CMV. Then, we will determine if that activation is due to CMV antigen presentation by the serum-derived MDMs, and whether statin treatment of the MDMs, which inhibits CMV replication in vitro, directly impairs their T cell activating capacity. Our studies may define mechanisms whereby chronic viral infection drives T cell- mediated vascular pathology and may identify novel targets beyond traditional risk factors to prevent/treat CVD in PWH and PWoH. Furthermore, understanding the role of CMV in CVD, and whether its activity is susceptible to statins, will help inform the interpretation of the A5332/REPRIEVE (pitavastatin) and A5383/ELICIT (letermovir) trials in PWH.

Coastal Community Foundation of South Carolina

Coastal Community Foundation of South Carolina ($300M in assets) supports nonprofits in SC through grants focused on education, environment, community development, arts. Awards range from $1,000 to $75,000.

NIDA - National Institute on Drug Abuse

PROJECT SUMMARY/ABSTRACT Despite the effectiveness of antiretroviral therapies (ART) in reducing vertical transmission, maternal HIV infection and ART exposure during pregnancy is associated with immune dysregulation in mothers, along with inflammation and significant pathology in the placenta. Compounding these risks is the increasing prevalence of substance abuse among pregnant women and people living with HIV. Compared with the general population, HIV-positive women had higher use of marijuana (15% vs 7%) and cocaine/crack (17% vs 0.1%), and recent findings suggest that 6-18.3% of pregnant women report using illicit drugs throughout gestation. Despite this increase, little is known about the impact of comorbid substance use and HIV/ART on the placenta. In this study we seek to fill this critical knowledge gap by elucidating the mechanisms driving placental dysfunction in pregnant women living with HIV with comorbid substance use and examine how cocaine and/or cannabis use may exacerbate viral infectivity, inflammation, and ART efficacy at the maternal- fetal interface. We hypothesize cocaine and cannabis polysubstance use antagonize placental ART transport and metabolism through PXR signaling, which promotes HIV replication, inflammatory responses, and placental abnormalities associated with adverse maternal and fetal outcomes. We will address this by evaluating: pharmacologic mechanisms by which comorbid substance use and HIV alter ART placental efficacy (Aim 1), immunologic and virologic mechanisms underlying effects of comorbid substance use and HIV/ART on the placenta (Aim 2), and evaluate whether HIV, ART and/or comorbid substance use is associated with dysfunction and inflammation in placentae and maternal blood from HIV (+) and (-) pregnancies (Aim 3).

NIAID - National Institute of Allergy and Infectious Diseases

Abstract Since its inception in 2011, the Martin Delaney Collaboratory program has made important advances towards a cure for HIV. In response to the Martin Delaney Collaboratories (MDC) for HIV Cure Research RFA, we seek to continue to advance the field by discovery of successful modalities to cure HIV infection. We will expand our expertise and work toward a better understanding of persistent HIV infection, the discovery of novel approaches to disrupt latency, methods to clear the HIV reservoir, and identification of strategies to control viral rebound. By building on the significant advances that we have made to develop, implement, and execute a suite of pre-clinical experiments that represent the most advanced and novel concepts, we will continue to pursue our central unifying hypothesis that reversing HIV latency such that viral proteins are expressed, in parallel with interventions that speed the clearance of cells emerging from latent infection, will ultimately lead to eradication of persistent HIV infection. In parallel to the efforts to clear the infection, we will pursue interventions to prevent rebound of viremia after ART interruption. We will leverage a broad portfolio of tools from both academic and industry partners, and apply new discoveries, demonstrating proof-of-concept for clinical initiatives. We will engage academic scientists and clinicians, industry investigators, and the community to a) define novel targets to destabilize proviral genomes that persist despite antiretroviral therapy (ART) b) define novel approaches to block proviral establishment c) develop and deploy novel effectors to clear viral reservoirs, d) delineate effective strategies to prevent rebound viremia that might emanate from such reservoirs after ART is discontinued and e) create bridges to the community to improve the understanding of and access to HIV cure research and clinical trials. Our initial efforts will focus on biology discovery to illuminate new host targets for latency reversal, and the validation of the novel biological concept of latency prevention. Universal strategies for proviral control or clearance will be developed and tested, including those based on HLA-E targeting, eCD4, and CD4 mimetics. Our major recent advance in latency reversal via NF-kB signaling will be further developed in both non-human primate and humanize mice models, in combination with candidates to clear infected cells. We envision an iterative process with insights gained in ex vivo and pre-clinical studies, carried forward to enhance the next step in clinical development and, importantly, fed back to scientists to validate assays or hypotheses, and explore new directions. As we have done in the past, we will develop human clinical trials to address questions and test concepts developed in our work through funding mechanisms distinct from CARE. We are dedicated to working together in a nimble program, with our research direction following our discoveries. Together we will catalyze advances that will ultimately lead to the eradication of HIV infection.

Belltown Collage Community Project

May 9th through June 7th Collage-O-Rama will be a drop-in location at Slip Gallery, 2301 1st Ave, for the public to make art and make friends, regardless of previous art experience level, with all supplies provided. The project enables free access to artists from a variety of backgrounds who are willing to share knowledge and information about resources. The approachable art form of collage allows visitors to create and display their work, even if it is their first time doing so. This project will be completd by July 31, 2025.

Colorado Creative Industries

Colorado Creative Industries provides grants to support arts and cultural programming, artist fellowships, arts education, and community-based arts projects across CO.

Colorado Creative Industries

Colorado Creative Industries supports Creative Districts — defined areas where arts and culture are developed as economic and community development tools — providing grants to certified Creative Districts across Colorado.

Colorado Creative Industries

Colorado Creative Industries provides general operating support grants to Colorado arts organizations, enabling them to deliver arts programming, build capacity, and expand access to arts and culture statewide.

Columbia Basin Trust

Columbia Basin Trust supports residents of the Columbia Basin region of BC through grants for community development, arts, environment, youth, and economic initiatives.

Peace Peloton

The Columbia City Night Market Holiday Series will bring neighbors together for two vibrant community events on November 15 and December 20, 2025. As a trusted South Seattle mainstay, the Market strengthens small businesses, prioritizes Black- and BIPOC-owned vendors, and provides a joyful, inclusive space where art, music, food, and culture thrive. With four years of proven impact, the Night Market drives critical holiday revenue for local merchants while fostering equity and belonging. The anticipated project completion date is January 31, 2026.

NIA - National Institute on Aging

PROJECT SUMMARY: OVERALL The Columbia University (CU) – Weill Cornell Medicine (WCM) Center for AIDS Research (CFAR) is a partnership between two large New York City (NYC) academic institutions, each with an expanding investment in HIV research and connected by the NewYork-Presbyterian hospital system, which spans four NYC counties designated as priority high-burden jurisdictions by the US Ending the HIV Epidemic (EHE) initiative. The overall specific aims of the CU-WCM CFAR are to (1) catalyze innovative, interdisciplinary, inter-institutional HIV research that addresses key HIV research priorities for ending the epidemic in NYC and beyond; (2) engage and support career development of HIV researchers, including early-career investigators (ECIs) and investigators new to HIV; and (3) advance community-engaged participatory research that promotes health for all people. The CU-WCM CFAR will accomplish these goals by establishing, engaging, and working through six Cores: The Administrative Core will provide leadership and management; implement strategic planning; and stimulate communication, collaboration, and capacity building. The Developmental Core will provide grant funding awards; mentoring and career development for new investigators; and provide resources, training, and feedback for mentors to improve their skills. The Structural Immunology Core will provide state-of-the-art imaging and immunological technologies; molecular structure determination; and bioinformatics to understand antibody-virus co-evolution, and structural modeling. The Virology Core will provide specialized assays to measure virus replication, infectivity, and cell susceptibility to infection; comprehensive reservoir characterization; and training in these methodologies. The Clinical Research Core will provide consultative support across the course of a study ranging from study design and biostatistical planning to participant recruitment, and data analysis. The Behavioral, Implementation and Community Sciences Core will support investigators engaged in behavioral, implementation, health services, and community science research and catalyze bi-directional collaborations with communities. We also will establish a Scientific Working Group – Integrating Systems of Care to End the HIV Epidemic – that will bring together a group of dynamic multi-sector collaborators to develop a robust research agenda that addresses fragmentation of care for HIV, mental health, and substance use care co-morbidities. The CU-WCM CFAR will add value to our institutions’ existing strong research portfolios through scientific leadership and strategic planning that builds synergistic new collaborations, enhances community engagement on HIV research and health, and supports innovation and research productivity as well as the next generation of leading HIV researchers.

NIAID - National Institute of Allergy and Infectious Diseases

PROJECT SUMMARY With the most people ever in history currently living with HIV, stopping the HIV epidemic remains imperative. Combination antiretroviral therapy (ART) limits viral replication, but is not curative. Thus, there is an urgent need to design a functional cure via elimination of the viral reservoir. We recently found that the combination of antiretroviral therapy, broadly neutralizing antibodies, and CCR5 blockade were able to completely clear establishment of infection in newborn macaques when delivered by day three post-infection. However, it remains unclear how far post-infection this treatment window extends in newborns and if this treatment is also effective in adults. In specific aim 1, we will systematically identify the window of opportunity for this novel triple therapy treatment to clear the latent reservoir by delaying treatment multiple days. In specific aim 2, we will determine if this remarkable clearance of reservoir establishment via triple therapy is also effective in adults infected via sexual transmission. Because all three components of this triple therapy are currently being tested individually in humans, successful completion of the aims here will set the stage for clinical trials to for HIV cure.

NCI - National Cancer Institute

Project Abstract Many solid cancers are inoperable due to either tumor size or because the tumor is attached to, or near, major blood vessels, vital organs or other critical tissues. Focal ablation modalities utilizing a variety of energy forms to destroy/debulk tumor tissues are frequently used in the management of inoperable solid cancers. More than 45,000 tumor ablation procedures are performed each year. Three thermal ablation techniques, radiofrequency ablation (RFA), cryoablation (CA) and microwave ablation (MWA), account for more than 80% of all procedures, but residual tumor deposits often lead to recurrence rates that are 2 to 10 times higher than recurrence rates following surgical resection. As a result, patients with inoperable tumors have worse survival outcomes compared to patients with resectable tumors. Integrated Nanosecond Pulse Irreversible Electroporation (INSPIRE) is a novel, minimally invasive solid tumor ablation modality. This thermally-regulated approach uses ultrashort alternating polarity electrical pulses to destabilize tumor cell membranes while preserving the integrity of nearby vital structures. A key advantage of INSPIRE, which forms the crux of this proposal is the flexibility in energy delivery and numerous parameters combinations that allows us to modulate cell death mechanisms to favor immunogenic pathways, and subsequent antitumor immune responses. Induction of robust antitumor immunity following focal ablation is crucial for eliminating residual tumor cells and preventing local or distant recurrence which can be enhanced with secondary immunotherapy agents such as checkpoint inhibitors. Based on our preliminary studies, we hypothesize that there is a ‘best’ or most immunogenic INSPIRE protocol which maximizes the resultant antitumor immune. We further hypothesize that an adjunctive immunotherapy can boost the INSPIRE-induced antitumor response, thus enhancing both local and systemic tumor control. These hypotheses will be tested in an aggressive, transplantable murine melanoma model before translation into comparative oncology trials in pet dogs with spontaneous melanomas via three aims: Aim 1: Develop and validate INSPIRE protocols to maximize tumor-specific immunity; Aim 2: Evaluate the timing of adjunctive immunotherapy relative to INSPIRE; Aim 3: Validation of Combinatorial INSPIRE in a Spontaneous Large Animal Model of Disease. These aims will determine the treatment parameters which maximize immune stimulation via INSPIRE, improve systemic anti- tumor immune responses via optimized adjunctive immunotherapy regimens, and demonstrate clinical superiority of this combined approach in a relevant large animal model. Our long term goal is to develop a novel, minimally invasive focal treatment paradigm that is capable of preventing recurrences and eliminating metastatic deposits. Successful completion of the proposed project will support further translation of INSPIRE plus adjunctive immunotherapy into human trials while providing a state-of-the-art treatment for thousands of companion animals per year.

U.S. National Science Foundation

TheCombustion and Fire Systemsprogram is part of the Transport Phenomena cluster, which also includes 1) theFluid Dynamicsprogram; 2) theParticulate and Multiphase Processesprogram; and 3) theThermal Transport Processesprogram. The goal of theCombustion and Fire Systemsprogram is to<span>create new knowledge to support advances in clean energy, climate change mitigation, a cleaner environment and public safety.</span> The program endeavors to createfundamental scientific knowledge that is needed for safe, clean and useful combustion applications and for mitigating the effects of fire.The program aims to identify and understand the controlling basic principles and to use that knowledge to create predictive capabilities for designing and optimizing practical combustion devices and understanding fire. Important outcomesfor this program include: <ul type="disc"> <li>broad-based tools &mdash; experimental, theoretical, andcomputational &mdash; that can be applied to a variety of problems in combustion technologies and fire;</li> <li>science and technology for clean and efficient generation of power;</li> <li>discoveries that enable clean environments (for example, by reduction in combustion-generated pollutants); and</li> <li>enhanced public safety and climate change mitigation through research on wildland and building fire growth, inhibition, and suppression.</li> </ul> Research areas of interest for this program include: <ul type="disc"> <li>Basic combustion science: Combustion of gas, liquid, and solid fuels over abroad range of temperatures, pressures, and compositions; combustion at supercritical conditions; advanced propulsion concepts; flame synthesis ofmaterials; integration of fuel design and combustion; control of reaction pathways; development of chemical kinetics models, analytical and numerical predictive methods, and advanced diagnostic tools.</li> <li>Combustionscience related to clean energy: Increasing efficiency and reducing pollution; production and use of renewable and/or carbon-free fuels; biomass pyrolysis, gasification, and oxidation; technologies such as oxy-fuel combustion and chemical looping combustion for carbon capture.</li> <li>Fireprevention: Improved understanding of building and wildland fires to prevent their spread, inhibit their growth, and suppress them; prediction and mitigation of fires in the wildland-urban interface.</li> <li>Turbulence-chemistry interactions:Fundamental understanding of turbulent flow interactions with finite-rate chemical kinetic pathways at high Reynolds and Karlovitz number conditions, including but not limited to: (1) fundamental experiments to generate physico-chemical data to reduce theuncertainty of combustion chemistry and turbulent combustion models; (2)spatially/temporally well-resolved, multi-scale/multi-physics computations;novel approaches of developing embedded multi-scale direct numericalsimulation (DNS) of complex geometries and data-assimilations forincorporating measured data from the state-of-art in situ diagnostic approaches; (3) other innovative approaches on development and validation of predictive computational methods. NOTE: This is an NSF-AFOSR (Air Force Office of Scientific Research) joint funding area. Proposals will be jointly reviewed by NSF and AFOSR using the NSF merit reviewprocess.Actual funding format and agency split for an award(depending on availabilityof funds) will be determined after the proposal selection process. The AFOSR program that participates in this initiative is the program on Energy, Combustion, and Nonequilibrium Thermodynamics.</li> </ul> Innovative proposals outside of these specific interest areas may be considered.However, prior to submission, it is recommended that the Principal Investigator contact the program director to avoid the possibility of the proposal being returned without review. <div> <div id="_com_1"> INFORMATION COMMON TO MOST CBET PROGRAMS </div> </div> Proposals should address the novelty and/or<a href="http://www.nsf.gov/about/transformative_research/faq.jsp">potentially transformative nature</a>of the proposed work compared to previous work in the field.Also, it is important to address why the proposed work is important in terms of engineering science, as well as to also project the potential impact on society and/or industry of success in the research.The novelty or potentially transformative nature of the research should be included, as a minimum, in the Project Summary of each proposal. The duration of unsolicited proposal awards in CBET is generally up to three years. Single-investigator award budgets typically include support for one graduate student (or equivalent) and up to one month of PI time per year(awards for multiple investigator projects are typically larger). Proposal budgets that are much larger than typical should be discussed with the program director prior to submission. Proposers can view budget amounts and other information from recent awards made by this program via the &ldquo;What Has Been Funded (Recent Awards Made Through This Program, with Abstracts)&rdquo; link towards the bottom of this page. Faculty Early Career Development(CAREER)program proposals are strongly encouraged.Award duration is five years.The submission deadline for Engineering CAREER proposals is in July every year. Learn more in the<a href="https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=503214">CAREER program description</a>. Proposals for Conferences, Workshops, and Supplements: PIs are strongly encouraged to discuss their requests with the program director before submission of the proposal. Grants forRapid Response Research(RAPID)andEArly-concept Grants for Exploratory Research(EAGER)are also considered when appropriate.Please note that proposals of these types must be discussed with the program director before submission.Grant Opportunities for Academic Liaison with Industry (GOALI)proposals that integrate fundamental research with translational results and are consistent with the application areas of interest to each program are also encouraged. Please note that RAPID, EAGER, and GOALI proposals can be submitted anytime during the year. Details about RAPID, EAGER, and GOALI are available in the Proposal &amp; Award Policies &amp; Procedures Guide (PAPPG), Part 1, Chapter II, Section E: Types of Proposals. Compliance: Proposals that are not compliant with the<a href="https://www.nsf.gov/publications/pub_summ.jsp?ods_key=pappg">Proposal &amp; Award Policies &amp; Procedures Guide (PAPPG)</a>will be returned without review.

U.S. National Science Foundation

The Combustion and Fire Systems program is part of the Transport Phenomena cluster, which also includes 1) the Fluid Dynamics program; 2) the Particulate and Multiphase Processes program; and 3) the Thermal Transport Processes program. The goal of the Combustion and Fire Systems program is to create new knowledge to support advances in clean energy, climate change mitigation, a cleaner environment and public safety. The program endeavors to create fundamental scientific knowledge that is needed for safe, clean and useful combustion applications and for mitigating the effects of fire. The program aims to identify and understand the controlling basic principles and to use that knowledge to create predictive capabilities for designing and optimizing practical combustion devices and understanding fire. Important outcomes for this program include: broad-based tools experimental, theoretical, and computational that can be applied to a variety of problems in combustion technologies and fire; science and technology for clean and efficient generation of power; discoveries that enable clean environments (for example, by reduction in combustion-generated pollutants); and enhanced public safety and climate change mitigation through research on wildland and building fire growth, inhibition, and suppression. Research areas of interest for this program include: Basic combustion science: Combustion of gas, liquid, and solid fuels over a broad range of temperatures, pressures, and compositions; combustion at supercritical conditions; advanced propulsion concepts; flame synthesis of materials; integration of fuel design and combustion; control of reaction pathways; development of chemical kinetics models, analytical and numerical predictive methods, and advanced diagnostic tools. Combustion science related to clean energy: Increasing efficiency and reducing pollution; production and use of renewable and/or carbon-free fuels; biomass pyrolysis, gasification, and oxidation; technologies such as oxy-fuel combustion and chemical looping combustion for carbon capture. Fire prevention: Improved understanding of building and wildland fires to prevent their spread, inhibit their growth, and suppress them; prediction and mitigation of fires in the wildland-urban interface. Turbulence-chemistry interactions: Fundamental understanding of turbulent flow interactions with finite-rate chemical kinetic pathways at high Reynolds and Karlovitz number conditions, including but not limited to: (1) fundamental experiments to generate physico-chemical data to reduce the uncertainty of combustion chemistry and turbulent combustion models; (2) spatially/temporally well-resolved, multi-scale/multi-physics computations; novel approaches of developing embedded multi-scale direct numerical simulation (DNS) of complex geometries and data-assimilations for incorporating measured data from the state-of-art in situ diagnostic approaches; (3) other innovative approaches on development and validation of predictive computational methods. NOTE: This is an NSF-AFOSR (Air Force Office of Scientific Research) joint funding area. Proposals will be jointly reviewed by NSF and AFOSR using the NSF merit review process. Actual funding format and agency split for an award (depending on availability of funds) will be determined after the proposal selection process. The AFOSR program that participates in this initiative is the program on Energy, Combustion, and Nonequilibrium Thermodynamics. Innovative proposals outside of these specific interest areas may be considered. However, prior to submission, it is recommended that the Principal Investigator contact the program director to avoid the possibility of the proposal being returned without review. INFORMATION COMMON TO MOST CBET PROGRAMS Proposals should address the novelty and/or potentially transformative nature of the proposed work compared to previous work in the field. Also, it is important to address why the proposed work is important in terms of engineering science, as well as to also project the potential impact on society and/or industry of success in the research. The novelty or potentially transformative nature of the research should be included, as a minimum, in the Project Summary of each proposal. The duration of unsolicited proposal awards in CBET is generally up to three years. Single-investigator award budgets typically include support for one graduate student (or equivalent) and up to one month of PI time per year (awards for multiple investigator projects are typically larger). Proposal budgets that are much larger than typical should be discussed with the program director prior to submission. Proposers can view budget amounts and other information from recent awards made by this program via the What Has Been Funded (Recent Awards Made Through This Program, with Abstracts) link towards the bottom of this page. Faculty Early Career Development (CAREER) program proposals are strongly encouraged. Award duration is five years. The submission deadline for Engineering CAREER proposals is in July every year. Learn more in the CAREER program description. Proposals for Conferences, Workshops, and Supplements: PIs are strongly encouraged to discuss their requests with the program director before submission of the proposal. Grants for Rapid Response Research (RAPID) and EArly-concept Grants for Exploratory Research (EAGER) are also considered when appropriate. Please note that proposals of these types must be discussed with the program director before submission. Grant Opportunities for Academic Liaison with Industry (GOALI) proposals that integrate fundamental research with translational results and are consistent with the application areas of interest to each program are also encouraged. Please note that RAPID, EAGER, and GOALI proposals can be submitted anytime during the year. Details about RAPID, EAGER, and GOALI are available in the Proposal &amp; Award Policies &amp; Procedures Guide (PAPPG), Part 1, Chapter II, Section E: Types of Proposals. Compliance: Proposals that are not compliant with the Proposal &amp; Award Policies &amp; Procedures Guide (PAPPG) will be returned without review.

Seattle Repertory Theater

Seattle Rep will produce a Community Sing-Along at one performance during the run of the musical Come From Away. The Community Sing-Along will be free to the public and led by volunteers who will take free musical theater workshops in advance of the event to learn the music and lead the audience in song. Up to 669 people will be able to enjoy a free performance of this world-renowned musical and feel closer to the art onstage by singing together with professional actors and community members. The free event will be held on December 31, 2025, at 12Pm in Seattle Rep’s Bagley Wright Theater located at 155 Mercer St, Seattle WA 98109.

National Endowment for the Humanities

COMMEMORATING AMERICA?S 250 [CIVIC SPIRIT?S COMMEMORATING AMERICA?S 250 PROGRAM WILL HONOR THE NATION?S SEMIQUINCENTENNIAL BY ENGAGING EDUCATORS AND THE PUBLIC IN CIVIC REFLECTION AND HISTORICAL LEARNING. THROUGH A YEAR-LONG WE THE EDUCATORS SERIES, MIDDLE AND HIGH SCHOOL TEACHERS IN FAITH-BASED SCHOOLS WILL EXPLORE FOUNDING TEXTS, PIVOTAL MOMENTS, AND CIVIC VIRTUES WHILE GAINING TOOLS TO FOSTER THOUGHTFUL CLASSROOM DIALOGUE. COMPLEMENTING THIS, THE WE THE PEOPLE SERIES WILL BRING SCHOLARS AND CITIZENS TOGETHER FOR LECTURES, TEXT-BASED DISCUSSIONS, AND CIVIL DISCOURSE ON AMERICAN PRINCIPLES AND DEMOCRATIC DEBATES. TOPICS WILL INCLUDE THE DECLARATION OF INDEPENDENCE, THE CONSTITUTION, CIVIC IDENTITY, FAITH AND DEMOCRACY, AND THE ROLE OF THE ARTS IN CIVIC CULTURE. THESE PROGRAMS WILL CREATE LASTING RESOURCES, STRENGTHEN CIVIC EDUCATION, AND MODEL PLURALISTIC DIALOGUE, ENSURING THE 250TH ANNIVERSARY SERVES AS A CATALYST FOR ENDURING CIVIC ENGAGEMENT.]

Lesley University College of Art and Design (LUCAD), Community Design Studio

Common Exchange Newspaper

Lesley University College of Art and Design (LUCAD), Community Design Studio

Common Exchange Newspaper

Communities Foundation of Texas

Communities Foundation of Texas ($2.2B in assets) supports nonprofits in TX through grants focused on education, community development, arts, health. Awards range from $5,000 to $250,000.

SouthEast Effective Development

Columbia City Gallery (CCG) requests funding to establish a community advisory task force to help realign our practices with the changing needs of Southeast Seattle. Our goal is to expand pathways for participation for BIPOC Southeast Seattle artists and organizations, and to ensure that our exhibitions and membership reflect the SE Seattle community. To better understand community needs, we will engage with five BIPOC artists and local arts advocates. They will review the Gallery's operating model, which as a cooperative requires member artists to pay monthly dues and work gallery shifts, and identify ways to shift towards a more equitable model. We will develop plants to reduce barriers to participation for underserved artists and better reflect the diversity of 98118. The group will meet twice/month for 3 months. We also plan to work with an EDI consultant to ensure the process is structured in an equity-centric way.

International Capoeira Angola Foundation - Seattle

Over the next 12 months the International Capoeira Angola Foundation will host a series of monthly events to showcase cultural arts from the African Diaspora. The location is the Union Cultural Center, 803 S. King St. The community will be brought together to share, learn, and participate in the vibrant cultures found in the region. The program will begin in January of 2020 and will conclude in December.